First-in-human experience with Aortix intraaortic pump.
Amit N VoraWilliam Schuyler JonesAdam D DeVoreAdrian EbnerWilliam CliftonManesh R PatelPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
Aortix, a novel pMCS device, was successfully deployed and retrieved in all initial patients undergoing high-risk PCI. We noted no significant hemolysis with temporary use of this axial flow device. Improvement in eGFR suggests a potential renal protective effect and is an important area for future investigation in patients with impaired left ventricular function and renal dysfunction.
Keyphrases
- patients undergoing
- left ventricular
- acute myocardial infarction
- endothelial cells
- small cell lung cancer
- coronary artery disease
- epidermal growth factor receptor
- heart failure
- percutaneous coronary intervention
- oxidative stress
- tyrosine kinase
- acute coronary syndrome
- current status
- atrial fibrillation
- mitral valve
- antiplatelet therapy
- st segment elevation myocardial infarction
- pluripotent stem cells
- left atrial
- st elevation myocardial infarction
- red blood cell